Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sandostatin LAR Depot · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Sandostatin LAR Depot | DRUG | - |
Inclusion Criteria: You may qualify for this study if you: * are between the ages of 18-70 (male or female) * are at least moderately obese (BMI \> 30 kg/m2 or approximately 30 or more pounds overweight) * and pass an oral glucose tolerance test (a 3 hour test to determine if your body produces to...
Sandostatin LAR Depot is used for primary insulin hypersecretion (PIH), a condition of excess insulin secretion, in patients who also have at least moderate obesity. It is being investigated as a treatment for this metabolic condition.
Sandostatin LAR Depot is developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS.
Sandostatin LAR Depot is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
Sandostatin LAR Depot has one completed Phase 2 clinical trial, identified as NCT00094146. This trial enrolled 160 participants with primary insulin hypersecretion and at least moderate obesity in the United States. The trial was randomized and double-blind.
Sandostatin LAR Depot is a long-acting release formulation of Sandostatin (octreotide). While both contain the same active ingredient, Sandostatin LAR Depot is designed for slow release over time, whereas Sandostatin is an immediate-release formulation.